NASDAQ:SESN

Sesen Bio Competitors

$2.52
-0.08 (-3.08 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.43
Now: $2.52
$2.63
50-Day Range
$2.42
MA: $2.78
$3.24
52-Week Range
$0.51
Now: $2.52
$3.57
Volume5.70 million shs
Average Volume6.72 million shs
Market Capitalization$426.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.22

Competitors

Sesen Bio (NASDAQ:SESN) Vs. FGEN, SAVA, ADCT, MYOV, PRLD, and IRWD

Should you be buying SESN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Sesen Bio, including FibroGen (FGEN), Cassava Sciences (SAVA), ADC Therapeutics (ADCT), Myovant Sciences (MYOV), Prelude Therapeutics (PRLD), and Ironwood Pharmaceuticals (IRWD).

Sesen Bio (NASDAQ:SESN) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and FibroGen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sesen Bio00203.00
FibroGen15202.13

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. FibroGen has a consensus price target of $45.8333, suggesting a potential upside of 146.81%. Given Sesen Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Sesen Bio is more favorable than FibroGen.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 75.1% of FibroGen shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Comparatively, 3.4% of FibroGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and FibroGen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sesen BioN/AN/A$-107,500,000.00($0.39)-6.46
FibroGen$256.58 million6.63$-76,970,000.00($0.89)-20.87

FibroGen has higher revenue and earnings than Sesen Bio. FibroGen is trading at a lower price-to-earnings ratio than Sesen Bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sesen Bio has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.

Profitability

This table compares Sesen Bio and FibroGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sesen BioN/AN/A-14.84%
FibroGen-191.78%-48.19%-27.72%

Summary

Sesen Bio beats FibroGen on 7 of the 12 factors compared between the two stocks.

Sesen Bio (NASDAQ:SESN) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and Cassava Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sesen Bio00203.00
Cassava Sciences00403.00

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. Cassava Sciences has a consensus price target of $35.3333, suggesting a potential downside of 15.00%. Given Sesen Bio's higher possible upside, research analysts plainly believe Sesen Bio is more favorable than Cassava Sciences.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Comparatively, 13.7% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and Cassava Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sesen BioN/AN/A$-107,500,000.00($0.39)-6.46
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-153.96

Cassava Sciences is trading at a lower price-to-earnings ratio than Sesen Bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sesen Bio has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares Sesen Bio and Cassava Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sesen BioN/AN/A-14.84%
Cassava SciencesN/A-22.01%-20.85%

Summary

Cassava Sciences beats Sesen Bio on 6 of the 10 factors compared between the two stocks.

Sesen Bio (NASDAQ:SESN) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and ADC Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sesen Bio00203.00
ADC Therapeutics01402.80

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. ADC Therapeutics has a consensus price target of $47.50, suggesting a potential upside of 98.00%. Given Sesen Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Sesen Bio is more favorable than ADC Therapeutics.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and ADC Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sesen BioN/AN/A$-107,500,000.00($0.39)-6.46
ADC Therapeutics$2.34 million706.29$-116,480,000.00($2.36)-10.17

Sesen Bio has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Sesen Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sesen Bio and ADC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sesen BioN/AN/A-14.84%
ADC TherapeuticsN/AN/AN/A

Summary

Sesen Bio beats ADC Therapeutics on 6 of the 10 factors compared between the two stocks.

Sesen Bio (NASDAQ:SESN) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and Myovant Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sesen Bio00203.00
Myovant Sciences03302.50

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. Myovant Sciences has a consensus price target of $31.1667, suggesting a potential upside of 71.72%. Given Sesen Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Sesen Bio is more favorable than Myovant Sciences.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 33.8% of Myovant Sciences shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Comparatively, 3.9% of Myovant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and Myovant Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sesen BioN/AN/A$-107,500,000.00($0.39)-6.46
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-5.39

Sesen Bio is trading at a lower price-to-earnings ratio than Myovant Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sesen Bio has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.99, indicating that its share price is 199% more volatile than the S&P 500.

Profitability

This table compares Sesen Bio and Myovant Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sesen BioN/AN/A-14.84%
Myovant SciencesN/AN/A-201.20%

Summary

Sesen Bio beats Myovant Sciences on 6 of the 10 factors compared between the two stocks.

Sesen Bio (NASDAQ:SESN) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and Prelude Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sesen Bio00203.00
Prelude Therapeutics03102.25

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. Prelude Therapeutics has a consensus price target of $54.25, suggesting a potential upside of 53.86%. Given Sesen Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Sesen Bio is more favorable than Prelude Therapeutics.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 76.2% of Prelude Therapeutics shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and Prelude Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sesen BioN/AN/A$-107,500,000.00($0.39)-6.46
Prelude TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Sesen Bio and Prelude Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sesen BioN/AN/A-14.84%
Prelude TherapeuticsN/AN/AN/A

Summary

Sesen Bio beats Prelude Therapeutics on 4 of the 6 factors compared between the two stocks.

Sesen Bio (NASDAQ:SESN) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sesen Bio and Ironwood Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sesen Bio00203.00
Ironwood Pharmaceuticals04102.20

Sesen Bio currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. Ironwood Pharmaceuticals has a consensus price target of $11.40, suggesting a potential upside of 11.87%. Given Sesen Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Sesen Bio is more favorable than Ironwood Pharmaceuticals.

Insider & Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sesen Bio and Ironwood Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sesen BioN/AN/A$-107,500,000.00($0.39)-6.46
Ironwood Pharmaceuticals$428.41 million3.83$21.50 million$0.5518.53

Ironwood Pharmaceuticals has higher revenue and earnings than Sesen Bio. Sesen Bio is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sesen Bio has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Profitability

This table compares Sesen Bio and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sesen BioN/AN/A-14.84%
Ironwood Pharmaceuticals27.77%-240.80%27.05%

Summary

Ironwood Pharmaceuticals beats Sesen Bio on 8 of the 13 factors compared between the two stocks.


Sesen Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71Analyst Report
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
Gap Down
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.13-1.9%$1.50 billion$7.51 million-5.22
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39News Coverage
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00Gap Down
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39-2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23-3.0%$1.18 billionN/A0.00Lockup Expiration
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.58-0.5%$1.16 billion$230,000.00-12.36
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.38-8.0%$1.15 billionN/A-8.88High Trading Volume
News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.54-1.6%$1.14 billionN/A0.00Unusual Options Activity
Lockup Expiration
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$30.78-0.7%$1.14 billionN/A0.00News Coverage
Omeros logo
OMER
Omeros
1.4$18.23-2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Gap Up
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.81-1.8%$1.09 billion$42.12 million-11.71News Coverage
Gap Down
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.50-1.4%$1.08 billionN/A-8.30Analyst Report
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.27-0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.42-7.3%$1.07 billion$120,000.00-3.86News Coverage
Gap Down
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.57-1.3%$1.07 billionN/A-8.82Analyst Report
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$22.16-2.8%$1.07 billion$1.52 million-11.79News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.27-1.9%$1.07 billionN/A-7.00
NKTX
Nkarta
1.8$32.28-1.6%$1.06 billionN/A0.00News Coverage
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.